MA
AXSM icon

Mutual Advisors’s Axsome Therapeutics AXSM Stock Holding History

Mutual Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,995
Closed -$202K – 869
2021
Q2 		$202K Buy
+2,995
New +$180K 0.01% 791
2021
Q1 		– Sell
-3,010
Closed -$245K – 776
2020
Q4 		$245K Sell
3,010
-269
-8% -$20.1K 0.02% 649
2020
Q3 		$234K Buy
+3,279
New +$256K 0.02% 600

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mutual Advisors's AXSM Position: Q3 2021 in Review

Mutual Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2021, closing a stake of 2,995 shares — an estimated $202K sold.

Mutual Advisors first reported a position in AXSM in Q3 2020 and held it in 3 quarters. The position peaked at $245K in Q4 2020. 171 funds tracked by Wall St. Rank hold AXSM as of Q3 2021.

  • Mutual Advisors reported no remaining Axsome Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Mutual Advisors sold 2,995 Axsome Therapeutics shares in Q3 2021, an estimated $202K.
  • Mutual Advisors first reported a position in Axsome Therapeutics in Q3 2020 and held it in 3 quarters.
  • Mutual Advisors's Axsome Therapeutics position peaked at $245K in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2021.

Based on Mutual Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.